Gilead Sciences Inc., of Foster City, Calif., said the FDA granted priority review to its NDA for the fixed-dose combination of bictegravir (BIC), an integrase strand transfer inhibitor, and emtricitabine/tenofovir alafenamide (FTC/TAF), a dual-nucleoside reverse transcriptase inhibitors backbone, for the treatment of HIV-1 infection. Gilead used a Priority Review Voucher to get their earlier Prescription Drug User Fee Act action date of Feb. 12, 2018. BIC/FTC/TAF is also under review by the EMA, which validated the application in the EU in July.